STADA with dynamic sales growth

09-Aug-2013 - Germany

In the first half of 2013, STADA Arzneimittel AG recorded a sustainable business development, in the context of which both Group sales and all reported key earnings figures increased.

“In the first half of 2013 we continued to increase the share of branded products in operating profit. This shows that we are right with our strategy to gradually expand this strong-margin core segment. The planned acquisition of the British OTC manufacturer Thornton & Ross will contribute to this end, with it we intend to strengthen our business activities in the British pharmaceutical market in the segment for branded products for self-medication, which is especially strategically important,“ said Hartmut Retzlaff, STADA's Chairman of the Executive Board.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance